title: Apparent modulation of CD20 by rituximab: an alternative explanation.
authors.forename: Mark S
authors.initials: MS
authors.lastname: Cragg
authors.forename: Mike C
authors.initials: MC
authors.lastname: Bayne
authors.forename: Timothy M
authors.initials: TM
authors.lastname: Illidge
authors.forename: Thomas
authors.initials: T
authors.lastname: Valerius
authors.forename: Peter W N
authors.initials: PW
authors.lastname: Johnson
authors.forename: Martin J
authors.initials: MJ
authors.lastname: Glennie
mesh_terms: D000888:Antibodies, Anti-Idiotypic / Q000494:pharmacology; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000187:drug effects*; D015536:Down-Regulation / Q000187:drug effects; D006801:Humans; D015448:Leukemia, B-Cell / Q000188:drug therapy / Q000473:pathology; D000069283:Rituximab; D014407:Tumor Cells, Cultured
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000069283:Rituximab